"Combining Chemo & Immunotherapy Did Not Help Patients: Hope To See Survival Level Off As Data Matures"
Nicholas Rohs, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai discusses treatment options for cancer patients. “I hope we see as the data matures that the survival levels off, and that there will be a group of patients that have long-term survival.” He added, “We’ve seen that with a lot of other frontline immunotherapies that some patients are living significantly longer when we get them access to these drugs early on.”
— Nicholas Rohs, MD, Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Mount Sinai Health System